Clinical Trial

Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-22
critical Primary endpoint(s) modified 2026-04-22
Trial Details
NCT Number NCT07378527
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Chronic Spontaneous Urticaria (CSU)
Enrollment 344 participants
Start Date 2026-02-13
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-21